4-~~21~~. The method according to claim 1~~8~~, wherein the cholinesterase inhibitor is an acetylcholinesterase inhibitor.

5-~~22~~. The method according to claim 4~~21~~, wherein the acetylcholinesterase inhibitor is selected from the group consisting of galanthamine, physostigmine, tetrahydroamino-acridine (tacrine), citicoline, velnacrine maleate, metrifonate, and heptastigmine.

6-~~23~~. The method according to claim 4~~21~~, wherein the cholinesterase inhibitor is a butyrylcholinesterase inhibitor.

7-~~24~~. The method according to claim 4~~21~~, wherein the at least one cholinesterase inhibitor is administered in an amount of from about 20 mg to about 200 mg per day.

B' cont. 8-~~25~~. A method for treating a patient suffering from Parkinson's Disease consisting of administering to said patient an effective amount of at least one cholinesterase inhibitor in combination with at least one medication conventionally administered to treat Parkinson's Disease.

9-~~26~~. The method according to claim 8~~25~~, wherein said at least one medication is levodopa.

10-~~27~~. The method according to claim 8~~25~~, wherein said at least one medication is selegilene.

11-~~28~~. The method according to claim 8~~25~~, wherein the patient is treated for rigidity associated with Parkinson's Disease.

12-~~29~~. The method according to claim 8~~25~~, wherein the patient is treated for dementia associated with Parkinson's Disease.